Clinical Trial Update: Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Ga-68 DOTATOC PET-CT imaging in the management of neuroendocrine tumors has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumors
• Neuroendocrine Tumors

Drugs mentioned

• Ga-68-DOTATOC (Gallium-68 DOTATOC)

Snippet

Sponsor: Sue O'Dorisio | Conditions: Neuroendocrine Tumors, Carcinoid Tumors | Phase 2 | Status: COMPLETED | Results posted: 2020-12-21